Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA BIOMED COMMENCES
RECRUITMENT FOR SECOND COHORT OF MELANOMA TRIAL
SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the
Company ) today announced that the first patient has been dosed for the second cohort of its clinical trial program for IMP321 in combination with KEYTRUDA being conducted in
Australia. The second cohort will recruit up to six patients with unresectable or metastatic melanoma that have had a suboptimal response to KEYTRUDA.
Interim data from the first patient cohort released in December 2016 indicate IMP321 is safe and well tolerated. On the basis of this safety data, the Data
Safety Monitoring Board (DSMB) gave approval for the second cohort to commence.
TACTI-mel (Two ACTive Immunotherapeutics in
melanoma) is a multicentre, open label, Phase I study in which patients with unresectable or metastatic melanoma will be dosed with IMP321 in combination with the PD-1 checkpoint inhibitor pembrolizumab (KEYTRUDA). The study will evaluate
safety as the primary endpoint and anti-tumour activity and the immune response to the combination as secondary endpoints.
IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active
immunotherapy drugs in which the patient s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour
antigens for a better anti-tumour CD8 T cell response.
Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products. Prima BioMed is
dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Prima s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune
response. IMP321 is a soluble LAG-3Ig fusion protein and an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier
NCT 02614833) and in a Phase I combination therapy trial in metastatic
melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). Additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being
developed by Prima s large pharmaceutical partners. Prima is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
further information please contact:
Matthew Beck, The Trout Group LLC
Australian Investors/Media:
Mr Matthew Gregorowski, Citadel-MAGNUS
Prima BioMed Ltd, Level 12, 95 Pitt Street, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889